Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

From first conversation right through to negotiations I would summarise your involvement in the process as (i) highly professional (ii) consultative and (iii) thoroughly supportive.
Ben , 2013

Bristol-Myers Squibb receives NICE backing for first-line Yervoy treatment

24 July 2014 11:01 in Pharmaceutical Company Product News

Bristol-Myers Squibb receives NICE backing for first-line Yervoy treatmentBristol-Myers Squibb's cancer drug Yervoy has been recommended for a new melanoma indication by the National Institute for Health and Care Excellence (NICE).

The UK regulator has published new guidance endorsing the use of the ipilimumab therapy as a first-line treatment for patients with advanced malignant melanoma when the full tumour cannot be removed, or the cancer has spread to other parts of the body.

Bristol-Myers Squibb has been able to prove the clinical benefits Yervoy can offer in these circumstances and has also agreed a patient access scheme with the Department of Health to sell the drug to the NHS at a discounted price.

Currently, there are few available therapy options for advanced melanoma, a disease for which prognoses are generally poor.

Professor Carole Longson, centre for health technology evaluation director at NICE, said: "New drugs such as ipilimumab can make a real difference. We already recommend it as a second-line treatment and are pleased to be able to extend that recommendation to first-line treatment too."

This comes after the firm announced that it has stopped a phase III trial of a new melanoma drug, nivolumab, earlier than expected due to the positive data generated thus far.ADNFCR-8000103-ID-801737356-ADNFCR

Other news stories from 24/07/2014

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd